ArticleBlood advances2026
IMP1 is a novel posttranscriptional regulator of early erythroid development and embryonic globin output.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
abstractThe RNA-binding protein IMP1 is a developmentally expressed, posttranscriptional regulator involved in mRNA stability and translation. In the erythroid lineage, IMP1 was found to be expressed in fetal but repressed in adult erythroid cells, being among the most differentially expressed proteins between these developmental stages, with levels decreasing sequentially as erythroid ontogeny progresses. To investigate its role in early erythroid cells, IMP1 was knocked down in the fetal erythroid line HUDEP-1. Knockdown did not alter expansion or differentiation. However, tandem mass tag-based proteomics revealed significant changes in the proteome, correlating with differential abundance of proteins in fetal compared with adult erythroid cells, indicating a role in specification of the fetal erythroid phenotype. Notwithstanding, there was no significant effect of IMP1 knockdown or knockout in HUDEP-1 on fetal γ-globin levels. However, there was a marked, significant reduction in embryonic ζ- and ε-globin protein levels, which, along with a strong association of IMP1 with their transcripts, supports direct posttranscriptional regulation by IMP1. Furthermore, IMP1 was found to be significantly more abundant in human induced pluripotent stem cells (iPSC)-embryonic erythroid cell surrogates than even fetal erythroid cells, suggesting a potentially more predominant role at this earlier, poorly characterized stage of erythroid development. This study uncovers a novel role for IMP1, reveals a previously unrecognized regulatory mechanism in early erythroid cells, and highlights the significant contribution of epitranscriptomic regulation in embryonic globin expression. As reactivation of embryonic globins in definitive erythroid cells holds therapeutic promise for hemoglobinopathies, targeting the mechanisms by which IMP1 enhances embryonic globin translation could complement transcriptional strategies, enabling therapeutic levels to be achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.